Released May 9, 2012, after the close
10-Q filed May 9, 2012, 39 days after period end · 0001144204-12-027198
Q1 2012 · 10-Q
Revenue$3.86M$3.86M no prior Q1 2011 on file+63.5% vs Q4 2011
Net Income-$5.90M-$5.90M N/M vs Q1 2011N/M vs Q4 2011
EPS Diluted$0.07$0.07 +16.7% vs Q1 2011no prior Q4 2011 on file
Gross Profit$2,408,000—
Operating Income-$6,065,000—
Operating Cash Flow-$6,281,000N/M
Free Cash Flowderived-$7,091,000N/M
Margins · derived
Gross margin62.4%
Operating margin-157.1%
Net margin-152.9%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | $3.86M | — |
| Net Income | -$5.90M | -$5.05M |
| EPS Diluted | $0.07 | $0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR